SCHEMBL20119975

SCHEMBL20119975

Cc1ccc(Cl)cc1N(C)C

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.52
GAA P10253 3/20 0.52
CYP3A4 P08684 1/20 0.48
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 2/20 0.39
RAPGEF4 Q8WZA2 1/20 0.38
FSCN1 Q16658 1/20 0.38
POLB P06746 2/20 0.38
KCNH2 Q12809 1/20 0.38
MAPK1 P28482 1/20 0.38
BLM P54132 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
TSHR P16473 2/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 2/20 0.37
CYP2A6 P11509 1/20 0.36
TP53 P04637 1/20 0.35
IDO1 P14902 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21396005 0.82 CYP3A4 (0.45) KMT2AGAACYP3A4KDM4EMEN1
SCHEMBL8233668 0.81 KMT2A (0.57) KMT2AGAACYP3A4KDM4EMEN1
SCHEMBL3789565 0.80 GAA (0.61) KMT2AGAACYP3A4FSCN1POLB
SCHEMBL28026747 0.79 CYP3A4 (0.42) KMT2AGAACYP3A4KDM4EMEN1
SCHEMBL1039636 0.78 GAA (0.54) KMT2AGAACYP3A4KDM4EFSCN1
SCHEMBL23084438 0.76 CYP3A4 (0.43) KMT2AGAACYP3A4KDM4EMEN1
SCHEMBL11695239 0.76 CYP3A4 (0.43) KMT2AGAACYP3A4MEN1POLB
SCHEMBL22791400 0.76 FSCN1 (0.43) KMT2AGAACYP3A4KDM4EMEN1
SCHEMBL24497945 0.76 TSHR (0.47) KMT2AGAACYP3A4KDM4EMEN1
SCHEMBL3185975 0.75 TDP1 (0.44) KMT2AGAACYP3A4KDM4ERAPGEF4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11760762-B2 Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors SIGNALRX PHARMACEUTICALS, INC. (US) 2023-09-19 US disclosed
US-11760762-B2 Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors SIGNALRX PHARMACEUTICALS, INC. (US) 2023-09-19 US disclosed
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2023-01-31 US disclosed
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-08-05 US disclosed
EP-3177616-B1 NOVEL ROUTES OF SYNTHESIS FOR THE PREPARATION OF SUVOREXANT SANDOZ AG (CH) 2021-02-24 EP disclosed
WO-2019183358-A2 WHOLE CELL PROCESSES TO PRODUCE NITROAROMATICS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2019-09-26 WO disclosed
WO-2018081456-A1 HIGHLY ACTIVE SELF-SUFFICIENT NITRATION BIOCATALYSTS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11760762-B2 Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors CDK1, CDKN1A, CDKL1 KMT2A 1487/4885GAA 4060/4885CYP3A4 2479/4885
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R KMT2A 1341/4885GAA 2646/4885CYP3A4 2798/4885
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC3R, MC1R, MC2R KMT2A 1341/4885GAA 2646/4885CYP3A4 2798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.